Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,444,115
  • Shares Outstanding, K 100,846
  • Annual Sales, $ 0 K
  • Annual Income, $ -188,920 K
  • EBIT $ -211 M
  • EBITDA $ -211 M
  • 60-Month Beta -1.51
  • Price/Sales 12.52
  • Price/Cash Flow N/A
  • Price/Book 2.70

Options Overview Details

View History
  • Implied Volatility 57.57% ( -4.68%)
  • Historical Volatility 42.93%
  • IV Percentile 18%
  • IV Rank 27.43%
  • IV High 185.90% on 04/12/24
  • IV Low 9.07% on 08/12/24
  • Put/Call Vol Ratio 1.19
  • Today's Volume 1,678
  • Volume Avg (30-Day) 643
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 10,371
  • Open Int (30-Day) 7,438

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.50
  • Number of Estimates 6
  • High Estimate -0.35
  • Low Estimate -1.16
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +21.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.31 unch
on 11/15/24
16.76 -20.58%
on 11/08/24
-1.52 (-10.25%)
since 10/15/24
3-Month
13.16 +1.14%
on 09/03/24
16.76 -20.58%
on 11/08/24
-0.92 (-6.47%)
since 08/15/24
52-Week
11.30 +17.79%
on 12/01/23
18.07 -26.34%
on 05/01/24
+1.24 (+10.27%)
since 11/15/23

Most Recent Stories

More News
Day One Biopharmaceuticals (DAWN) Stock Soars 11.3% on Strategic Milestones and Promising Outlook

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) surged 11.3% this morning, reflecting strong investor confidence fueled by a series of favorable developments. This biotech firm focused on advancing...

DAWN : 13.31 (-7.05%)
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

DAWN : 13.31 (-7.05%)
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

DAWN : 13.31 (-7.05%)
Day One Biopharmaceuticals (DAWN) Stock Soars 11.3% on Strategic Milestones and Promising Outlook

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) surged 11.3% this morning, reflecting strong investor confidence fueled by a series of favorable developments. This biotech firm focused on advancing...

DAWN : 13.31 (-7.05%)
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...

KZIA : 4.62 (-12.33%)
DAWN : 13.31 (-7.05%)
NVS : 103.06 (-0.33%)
Stock Index Futures Muted as Weak China Trade Data Weighs on Sentiment

June S&P 500 futures (ESM23) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.09% this morning as weak trade data from China stoked investor concerns over the strength of global demand....

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
PACW : 7.54 (-2.71%)
WAL : 90.38 (-1.20%)
INTC : 24.35 (-2.72%)
AMD : 134.90 (-2.84%)
COIN : 305.85 (+9.69%)
ITX.E.DX : 51.000 (+0.08%)
YEXT : 7.78 (-1.39%)
GDYN : 16.25 (-4.58%)
VXRT : 0.5801 (-7.92%)
DAWN : 13.31 (-7.05%)
Why Shares of Day One Pharmaceuticals Are Up Monday

The clinical-stage biotech released early trial news regarding its lead therapy candidate.

DAWN : 13.31 (-7.05%)
Stock Index Futures Mixed on Pressure from Rising Bond Yields, Oil Prices Rise After Saudi Output Cuts

June S&P 500 futures (ESM23) are up +0.01%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.25% this morning as market participants digested the U.S. debt ceiling agreement, while U.S. Treasury...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
LULU : 320.01 (-3.10%)
MMM : 129.79 (-1.91%)
AMZN : 202.61 (-4.19%)
VOLCB.S.DX : 23.500 (-2.81%)
MRO : 28.59 (-0.52%)
DVN : 38.47 (-2.31%)
OXY : 49.97 (-1.38%)
DBRG : 12.70 (+1.28%)
RAIN : 1.2100 (-1.63%)
EVAX : 1.4400 (-14.29%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 3.29 (-0.30%)
DAWN : 13.31 (-7.05%)
SWTX : 36.45 (-0.27%)
VSTM : 3.99 (-3.39%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 3.29 (-0.30%)
SWTX : 36.45 (-0.27%)
DAWN : 13.31 (-7.05%)
VSTM : 3.99 (-3.39%)
KNTE : 2.65 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 15.59
2nd Resistance Point 15.32
1st Resistance Point 14.82
Last Price 13.31
1st Support Level 14.05
2nd Support Level 13.77
3rd Support Level 13.27

See More

52-Week High 18.07
Fibonacci 61.8% 15.48
Fibonacci 50% 14.68
Fibonacci 38.2% 13.89
Last Price 13.31
52-Week Low 11.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar